<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01255956</url>
  </required_header>
  <id_info>
    <org_study_id>Restenoza II 4.0</org_study_id>
    <nct_id>NCT01255956</nct_id>
  </id_info>
  <brief_title>Restenosis Treatment With Rapamycin Eluting Stent or Paclitaxel Eluting Balloon Catheter (RESTENOZA)</brief_title>
  <acronym>ISRII</acronym>
  <official_title>Efficacy Evaluation of In-bare Metal Stent Restenosis Treatment With Rapamycin Eluting Stent or Paclitaxel Eluting Balloon Catheter. Study With Intravascular Ultrasound and Optical Coherence Tomography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Warsaw</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>KCRI</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Warsaw</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to compare rapamycin eluting stent and paclitaxel eluting balloon&#xD;
      catheter in the treatment of restenosis in bare metal stent.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study aims:&#xD;
&#xD;
        -  Clinical efficacy evaluation of different treatment's strategies, including&#xD;
           periprocedural and long-term endpoints defined as: death, myocardial infarction, brain&#xD;
           stroke, necessity of repeated revascularization&#xD;
&#xD;
        -  Evaluation of intravascular ultrasound (IVUS) as an optimisation method for direct and&#xD;
           long-term revascularization effects&#xD;
&#xD;
        -  Evaluation of optical coherence tomography as an optimisation method for direct and&#xD;
           long-term revascularization effects&#xD;
&#xD;
        -  Evaluation of late lumen loss and neointimal hyperplasia in stent in long-term follow-up&#xD;
&#xD;
        -  Analysis of direct and indirect medical costs of alternative treatment strategies&#xD;
&#xD;
      Study group:&#xD;
&#xD;
      200 patients with symptomatic restenosis evidenced angiographically in bare metal stent&#xD;
      implanted in native coronary artery. Patients will be randomised to 2 therapeutic groups:&#xD;
&#xD;
        -  Patients treated with rapamycin eluting stent (n=100)&#xD;
&#xD;
        -  Patients treated with paclitaxel eluting balloon catheter (n=100)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">July 2012</completion_date>
  <primary_completion_date type="Anticipated">July 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of repeated restenosis angiographically evidenced</measure>
    <time_frame>at 9 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Neointimal volume assessed by intravascular ultrasound (IVUS)</measure>
    <time_frame>at 9 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Late lumen loss and neointimal volume assessed by optical coherence tomography (OCT)</measure>
    <time_frame>at 9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of repeated target lesion revascularization (TLR)</measure>
    <time_frame>at 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of repeated target vessel revascularization (TVR)</measure>
    <time_frame>at 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of death</measure>
    <time_frame>at 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of myocardial infarction</measure>
    <time_frame>at 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of brain stroke</measure>
    <time_frame>at 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of in-stent thrombosis</measure>
    <time_frame>at 9 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>In-Stent Restenosis</condition>
  <arm_group>
    <arm_group_label>Rapamycin eluting stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients treated with rapamycin eluting stent (n=100)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paclitaxel eluting balloon catheter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients treated with paclitaxel eluting balloon catheter (n=100)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Rapamycin eluting stent implantation</intervention_name>
    <description>Rapamycin eluting stent implantation for in-stent restenosis treatment</description>
    <arm_group_label>Rapamycin eluting stent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Paclitaxel eluting balloon catheter</intervention_name>
    <description>Paclitaxel eluting balloon catheter for in-stent restenosis treatment</description>
    <arm_group_label>Paclitaxel eluting balloon catheter</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  at least 18 years of age&#xD;
&#xD;
          -  symptomatic restenosis in bare metal stent implanted in native coronary artery&#xD;
&#xD;
          -  angina pectoris&#xD;
&#xD;
          -  ischemia evidenced by non-invasive diagnostic tests&#xD;
&#xD;
          -  angiographically evidenced in-stent restenosis &gt; 50% assessed by quantitative coronary&#xD;
             angiography (QCA)&#xD;
&#xD;
          -  vessel diameter &gt; 2,5 mm&#xD;
&#xD;
        Clinical exclusion criteria:&#xD;
&#xD;
          -  myocardial infarction within less than past 72 hours&#xD;
&#xD;
          -  heart failure with left ventricular ejection fraction (LVEF) &lt; 30%&#xD;
&#xD;
          -  chronic renal failure with significant impairment of glomerular filtration (creatinine&#xD;
             &gt; 2 mg/dl)&#xD;
&#xD;
          -  hypersensitivity or contraindication to acetylsalicylic acid, clopidogrel, heparin,&#xD;
             abciximab, rapamycin, paclitaxel&#xD;
&#xD;
          -  hypersensitivity to contrast&#xD;
&#xD;
          -  other diseases that may cause significant deterioration in long-term prognosis&#xD;
&#xD;
          -  acute or chronic inflammatory diseases&#xD;
&#xD;
          -  patients who are unwilling to consent for participation in the study&#xD;
&#xD;
        Angiographic exclusion criteria:&#xD;
&#xD;
          -  significant stenosis in left main coronary artery (LM)&#xD;
&#xD;
          -  multivessel disease qualifying for coronary artery bypass grafting (CABG)&#xD;
&#xD;
          -  anatomical localization and morphology that preclude optimal percutaneous intervention&#xD;
             intervention's (PCI) result or intravascular ultrasound (IVUS) or optical coherence&#xD;
             tomography performance&#xD;
&#xD;
          -  vessel diameter &lt; 2,5 mm&#xD;
&#xD;
          -  restenotic lesion length &gt; 30 mm&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacek Legutko, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>II Department of Cardiology Medical College Jagiellonian University University Hospital in Krakow</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instytut Kardiologii w Warszawie-Aninie</name>
      <address>
        <city>Warszawa</city>
        <state>Alpejska 42</state>
        <zip>04-628</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Witkowski, MD, PhD</last_name>
      <phone>+48 22 812 41 64</phone>
    </contact>
    <investigator>
      <last_name>Adam Witkowski, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Katedra i Klinika Kardiologii Warszawskiego Uniwersytetu Medycznego</name>
      <address>
        <city>Warszawa</city>
        <state>Banacha 1a</state>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janusz Kochman, MD, PhD</last_name>
      <phone>+48 22 599 19 58</phone>
    </contact>
    <investigator>
      <last_name>Janusz Kochman, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinika Kardiologii z KlinikÄ… Kardiochirurgii Uniwersyteckiego Szpitala Klinicznego w Lodzi</name>
      <address>
        <city>Lodz</city>
        <state>Kniaziewicza 1/5</state>
        <zip>91-347</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zbigniew Peruga, MD, PhD</last_name>
      <phone>+48 42 251 62 21</phone>
    </contact>
    <investigator>
      <last_name>Zbigniew Peruga, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>II Department of Cardiology Medical College Jagiellonian University University Hospital in Krakow</name>
      <address>
        <city>Krakow</city>
        <state>Kopernika 17</state>
        <zip>31-500</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacek Legutko, MD, PhD</last_name>
      <phone>+48 12 424 71 81</phone>
    </contact>
    <investigator>
      <last_name>Jacek Legutko, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <study_first_submitted>December 6, 2010</study_first_submitted>
  <study_first_submitted_qc>December 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2010</study_first_posted>
  <last_update_submitted>January 24, 2011</last_update_submitted>
  <last_update_submitted_qc>January 24, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2011</last_update_posted>
  <responsible_party>
    <name_title>Medical University of Warsaw</name_title>
    <organization>Medical University of Warsaw</organization>
  </responsible_party>
  <keyword>restenosis</keyword>
  <keyword>ISR</keyword>
  <keyword>in-stent restenosis</keyword>
  <keyword>drug eluting stent</keyword>
  <keyword>rapamycin eluting stent</keyword>
  <keyword>paclitaxel eluting balloon catheter</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

